|
Mayne Pharma receives approval for epirubicin in the USA |
|
|
|
20 Sep 2006 |
Announced that it has received marketing authorisation for its freeze-dried epirubicin product from the US Food & Drug Administration (FDA).
MELBOURNE, Australia | Sep 19, 2006 | Mayne Pharma Limited (ASX:MYP) has today announced that it has received marketing authorisation for its freeze-dried epirubicin product from the US Food & Drug Administration (FDA).
Dr Thierry Soursac, Mayne Pharma's Chief Executive Officer and Managing Director commented "We are pleased to have received approval for this important oncology product at the formation of the market for generic epirubicin in the USA, showing once again the strength of our regulatory and intellectual property strategies."
Epirubicin, sold under the brand name Ellence®, generated sales of approximately US$68 million in the US market (source: IMS Health MAT June 2006).
SOURCE: Mayne Pharma Limited |
